How Genetic Variants Affect Drug Response (Pharmacogenomics)

Pharmacogenomics — the study of how genetic variation influences drug response — addresses one of the most fundamental questions in medicine: why do patients respond so differently to the same drug at the same dose? The answer lies in heritable differences in the genes encoding drug-metabolizing enzymes, drug transporters, drug targets, and immune response genes that collectively determine how an individual processes, responds to, and may develop adverse reactions to pharmacological agents.

Drug Metabolism: The CYP450 System

The cytochrome P450 (CYP) enzyme family metabolizes approximately 70–80% of clinically used drugs. Several CYP genes show dramatic genetic variation with major clinical consequences. CYP2D6 metabolizes codeine, many antidepressants, and tamoxifen; poor metabolizers (who lack functional CYP2D6) receive no analgesia from codeine and may not activate tamoxifen to its active metabolite, potentially reducing its breast cancer prevention efficacy. Ultra-rapid metabolizers (who carry extra gene copies) may develop opioid toxicity from standard codeine doses. CYP2C19 activates clopidogrel; poor metabolizers cannot form active drug and face dramatically elevated stent thrombosis risk after cardiac stenting — a finding that led to FDA boxed warning labeling and guideline recommendations for genetic testing before prescribing.

Drug Target Genetics: VKORC1 and Warfarin

Warfarin, the most widely prescribed oral anticoagulant for decades, has an extremely narrow therapeutic window with severe bleeding risk at supratherapeutic and thrombotic risk at subtherapeutic levels. Two genetic variants — VKORC1 (the warfarin target) and CYP2C9 (the warfarin-metabolizing enzyme) — together with age, weight, and drug interactions explain approximately 50% of interindividual warfarin dose requirements. Pharmacogenomic dosing algorithms incorporating these variants have been validated in clinical trials and are now available at point-of-care to guide initial warfarin dose selection.

HLA and Severe Drug Reactions

Human leukocyte antigen (HLA) variants mediate some of the most severe and potentially fatal drug reactions. HLA-B*57:01 carriers face a high risk of abacavir hypersensitivity reaction, a potentially life-threatening systemic immune reaction. Prospective HLA-B*57:01 screening before abacavir prescription has virtually eliminated this toxicity and is now mandatory standard of care. HLA-B*15:02 is associated with carbamazepine-induced Stevens-Johnson syndrome in Asian populations, requiring pre-prescription screening in affected populations. The Clinical Pharmacogenomics Implementation Consortium (CPIC) provides free, regularly updated drug-gene guidelines to support clinicians. For more on the genomic technologies enabling these discoveries, see our article on the Human Genome Project's 20 years of discoveries.

For more information, visit our homepage or our resources section.